The therapeutic effects of a-L-Guluronic acid in patients with ankylosing spondylitis

Comparing the effects of a-L-Guluronic acid with conventional Non-steroidal anti-inflammatory drugs on disease activity and inflammatory markers in patients with ankylosing spondylitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091813739N4

Enrollment

Registered

2016-10-10

Start date

2016-11-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing spondylitis. Ankylosing spondylitis

Interventions

Intervention 1: Intervention group will receive 1500 mg/day (three 500 mg tablets/day) of a-L-Guluronic acid orally for 12 weeks. Intervention 2: Control group will receive 1500 mg/day (three 500 mg t

Treatment - Drugs

Intervention group will receive 1500 mg/day (three 500 mg tablets/day) of a-L-Guluronic acid orally for 12 weeks.

Control group will receive 1500 mg/day (three 500 mg tablets/day) of plcebo orally for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients aged 18-45 years old; Diagnosis of "Definite AS" as defined by the modified New York criteria; Disease activity equal to BASDAI score = 4; Functional activity equal to BASFI score = 4; Each patient must sign written informed consent. Exclusion Criteria: History of fever and Infectious diseases; Positive pregnancy test or Lactation; Other collagen - vascular diseases; Other auto-immune diseases; Malignancies; Patients have enrolled another clinical trial study within last 4 weeks; Other concomitant diseases (Hepatic, renal, hematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The ASAS20 response criteria. Timepoint: 12 weeks after intervention (at the end of study). Method of measurement: Questionnaire.;Disease activity. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Questionnaire.;Physical function. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Questionnaire.	—

Secondary

Measure	Time frame
Serum level of CRP. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Turbidometry.;Level of ??ESR. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Observing with Westegren method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abbas Mirshafiey

Department of pathobiology, School of Public Health, Tehran University of Medical Sciences

mirshafiey@tums.ac.ir+98 21 8895 4913

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 4, 2026